{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T18:45:49Z","timestamp":1788201949733,"version":"build-2803163510"},"reference-count":17,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2022,1,12]],"date-time":"2022-01-12T00:00:00Z","timestamp":1641945600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,8,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Evidence-based treatment protocols are currently lacking for immune-mediated necrotizing myopathy (IMNM). In this multicentre retrospective study, we examined baseline clinical characteristics and treatment variables that may predict short-term outcomes of patients with IMNM.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Muscle biopsies from the John Hunter Hospital and the Royal Adelaide Hospital obtained between 2012 and 2019 were reviewed at a single laboratory at South Australia Pathology. All biopsies with histological features of IMNM were identified. Demographics of study subjects, clinical information and myositis-specific antibody status were recorded along with muscle strength, serum creatine kinase (CK) and treatment regimens at baseline and 3 and 6\u2009months. Primary outcome measures were muscle strength and serum CK at 3 and 6\u2009months. Mixed-effects regression models in a Bayesian framework were performed using the R statistical package.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Female sex, older age, initial prednisone dose and i.v. methylprednisolone were associated with greater improvement in serum CK. In patients with moderate\u2013severe disease at baseline, early IVIG was associated with greater improvement in hip flexor strength at 6\u2009months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Early IVIG was associated with clinical improvement in the short-term follow-up in IMNM. Female sex, older age, initial oral prednisone dose and initial use of i.v. methylprednisolone were associated with better biochemical improvement.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/rheumatology\/keac014","type":"journal-article","created":{"date-parts":[[2022,1,10]],"date-time":"2022-01-10T07:10:34Z","timestamp":1641798634000},"page":"3824-3829","source":"Crossref","is-referenced-by-count":16,"title":["Outcome predictors of immune-mediated necrotizing myopathy\u2014a retrospective, multicentre study"],"prefix":"10.1093","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2107-8555","authenticated-orcid":false,"given":"Jeremy X","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Rheumatology, John Hunter Hospital , New Lambton Heights, NSW"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Wilkinson","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Royal Adelaide Hospital , Adelaide, SA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Oldmeadow","sequence":"additional","affiliation":[{"name":"Hunter Medical Research Institute , New Lambton Heights, NSW"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vidya","family":"Limaye","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Royal Adelaide Hospital , Adelaide, SA"},{"name":"Discipline of Medicine, University of Adelaide , Adelaide, SA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3464-7438","authenticated-orcid":false,"given":"Gabor","family":"Major","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, John Hunter Hospital , New Lambton Heights, NSW"},{"name":"Faculty of Medicine, University of Newcastle , Newcastle, NSW, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,1,12]]},"reference":[{"key":"2022090108143077500_keac014-B1","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1007\/s11926-015-0548-6","article-title":"Immune-mediated necrotizing myopathy: update on diagnosis and management","volume":"17","author":"Basharat","year":"2015","journal-title":"Curr Rheumatol Rep"},{"key":"2022090108143077500_keac014-B2","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.semarthrit.2019.04.002","article-title":"Immune-mediated necrotising myopathy: a critical review of current concepts","volume":"49","author":"Day","year":"2019","journal-title":"Semin Arthritis Rheum"},{"key":"2022090108143077500_keac014-B3","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1136\/annrheumdis-2017-211468","article-title":"2017 European League Against Rheumatism\/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups","volume":"76","author":"Lundberg","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2022090108143077500_keac014-B4","first-page":"787","article-title":"More severe disease and slower recovery in younger patients with anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase-associated autoimmune myopathy","volume":"56","author":"Tiniakou","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"2022090108143077500_keac014-B5","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1007\/s00415-003-1027-y","article-title":"Necrotising myopathy, an unusual presentation of a steroid-responsive myopathy","volume":"250","author":"Bronner","year":"2003","journal-title":"J Neurol"},{"key":"2022090108143077500_keac014-B6","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.nmd.2017.09.016","article-title":"224th ENMC International Workshop: Clinico-sero-pathological classification of immune-mediated necrotizing myopathies Zandvoort, The Netherlands, 14\u201316 October 2016","volume":"28","author":"Allenbach","year":"2018","journal-title":"Neuromuscul Disord"},{"key":"2022090108143077500_keac014-B7","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1002\/mus.24541","article-title":"Clinical and genetic associations of autoantibodies to 3-hydroxy-3-methyl-glutaryl-coenzyme a reductase in patients with immune-mediated myositis and necrotizing myopathy","volume":"52","author":"Limaye","year":"2015","journal-title":"Muscle Nerve"},{"key":"2022090108143077500_keac014-B8","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1002\/acr.22920","article-title":"Longitudinal course of disease in a large cohort of myositis patients with autoantibodies recognizing the signal recognition particle","volume":"69","author":"Pinal-Fernandez","year":"2017","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2022090108143077500_keac014-B9","first-page":"CD003643","article-title":"Immunosuppressant and immunomodulatory treatment for dermatomyositis and polymyositis","volume":"3","author":"Gordon","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"2022090108143077500_keac014-B10","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1016\/j.semarthrit.2020.02.009","article-title":"Severe axial and pelvifemoral muscle damage in immune-mediated necrotizing myopathy evaluated by whole-body MRI","volume":"50","author":"Landon-Cardinal","year":"2020","journal-title":"Semin Arthritis Rheum"},{"key":"2022090108143077500_keac014-B11","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.2169\/internalmedicine.0303-17","article-title":"Development of necrotizing myopathy following interstitial lung disease with anti-signal recognition particle antibody","volume":"57","author":"Kusumoto","year":"2018","journal-title":"Intern Med"},{"key":"2022090108143077500_keac014-B12","doi-asserted-by":"crossref","first-page":"427","DOI":"10.3109\/03009742.2015.1132761","article-title":"Anti-HMGCR antibody-associated necrotizing myopathy: diagnosis and treatment illustrated using a case report","volume":"45","author":"Giudizi","year":"2016","journal-title":"Scand J Rheumatol"},{"key":"2022090108143077500_keac014-B13","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/s41584-020-00515-9","article-title":"Immune-mediated necrotizing myopathy: clinical features and pathogenesis","volume":"16","author":"Allenbach","year":"2020","journal-title":"Nat Rev Rheumatol"},{"key":"2022090108143077500_keac014-B14","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s13075-019-2093-6","article-title":"Statin-induced anti-HMGCR myopathy: successful therapeutic strategies for corticosteroid-free remission in 55 patients","volume":"22","author":"Meyer","year":"2020","journal-title":"Arthritis Res Ther"},{"key":"2022090108143077500_keac014-B15","doi-asserted-by":"crossref","first-page":"e513","DOI":"10.1212\/NXI.0000000000000513","article-title":"Seronegative patients form a distinctive subgroup of immune-mediated necrotizing myopathy","volume":"6","author":"Lim","year":"2019","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"2022090108143077500_keac014-B16","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1001\/jamaneurol.2015.1207","article-title":"Clinical features and treatment outcomes of necrotizing autoimmune myopathy","volume":"72","author":"Kassardjian","year":"2015","journal-title":"JAMA Neurol"},{"key":"2022090108143077500_keac014-B17","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1007\/s00296-019-04254-3","article-title":"Intravenous human immunoglobulin and\/or methylprednisolone pulse therapies as a possible treat-to-target strategy in immune-mediated necrotizing myopathies","volume":"39","author":"de Souza","year":"2019","journal-title":"Rheumatol Int"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keac014\/42502643\/keac014.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/61\/9\/3824\/45626741\/keac014.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/61\/9\/3824\/45626741\/keac014.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T04:34:43Z","timestamp":1662006883000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/61\/9\/3824\/6505193"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,12]]},"references-count":17,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2022,1,12]]},"published-print":{"date-parts":[[2022,8,30]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keac014","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,9,1]]},"published":{"date-parts":[[2022,1,12]]}}}